Skip to main navigation Skip to search Skip to main content

Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

  • Jennifer G. Robinson (Lead / Corresponding author)
  • , Helen M. Colhoun
  • , Harold E. Bays
  • , Peter H. Jones
  • , Yunling Du
  • , Corinne Hanotin
  • , Stephen Donahue

    Research output: Contribution to journal › Article › peer-review

    43   Link opens in a new tab Citations (Scopus)
    214 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies'. Together they form a unique fingerprint.
    Sort by

    Keyphrases

    Pharmacology, Toxicology and Pharmaceutical Science